• Femasys

  Led · Equity · Apr 2015

  Femasys develops FemBloc™, a non-surgical permanent contraception system intended to be delivered exclusively in the physician’s office. The company is advancing FemBloc through pivotal testing and has secured U.S. FDA Investigational Device Exemption (IDE) approval to launch a prospective, multi-center clinical trial to evaluate safety and pregnancy prevention. The clinical trial will enroll women who desire permanent birth control via occlusion of the fallopian tubes and is Femasys’ first trial to evaluate the complete FemBloc system for its intended use. Leadership includes President and CEO Kathy Lee-Sepsick and Mimi Zieman, M.D., Vice President of Clinical Affairs. Femasys closed a $40M Series C to support these clinical and regulatory efforts. Femasys is advancing non-surgical female sterilization medical devices and commercializes products for women's reproductive health. Its FemBloc™ Permanent Contraceptive System enables physicians to deliver a biomaterial through a catheter-based system. The company also markets FemVue® Saline-Air device for infertility diagnosis and the FemCerv® Endocervical Sampler for cervical cancer sampling. Led by President & CEO Kathy Lee-Sepsick, Femasys is based in Atlanta, GA. On July 20, 2015 the company secured a term loan facility from Silicon Valley Bank with an undisclosed amount, receiving initial funding and a conditional option for additional funding. Femasys said it will use the funds for working capital to support advancement of its device and had previously raised $10.2M in April 2015. Femasys is an Atlanta, GA-based developer of medical devices for the women’s healthcare market. Its flagship product is the FemBloc Permanent Contraceptive System, a non-surgical device that delivers a biomaterial via catheter to permanently block fallopian tubes, reducing patient risks and costs by eliminating anesthesia and permanent implants. The company also offers diagnostic products including the FemVue saline‑air device for infertility diagnosis and the FemCerv endocervical sampler for cervical cancer screening. Led by President and CEO Kathy Lee-Sepsick, Femasys is pursuing regulatory and commercialization goals for its product portfolio. It plans to use the recent financing to achieve an Investigational Device Exemption (IDE) milestone for FemBloc and to expand commercialization globally for its diagnostic products. Femasys was founded in 2004 in Suwanee, Georgia, and develops medical devices exclusively for use in the physician's office with a focus on women's healthcare. Its products are intended to enhance and improve treatment options while emphasizing patient comfort and convenience. The company describes itself as rapidly growing and is pursuing new product development and commercialization efforts. To support those efforts, Femasys obtained external financing to provide working capital. Management said the financing will position the company for continued growth and support its business lifecycle needs. GE Capital's involvement signals an institutional debt relationship to support the company's commercialization plans.

No current team members are available.